Overview

A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer

Status:
Completed

Trial end date:
2008-03-01

Target enrollment:

Participant gender:

Summary

Based on preclinical data, ZD1839 is considered a novel and promising therapeutic approach with potential application in the treatment of human breast cancer. Therefore it could be very important and clinically relevant to know if ZD1839 is capable of eliminating occult tumour cells circulating in the blood of breast cancer patients

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital of Crete

Treatments:

Gefitinib